Cardiometabolic News and Research

RSS
Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients

Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients

Orexigen Therapeutics announces data from CORDiabetes trial for Contrave

Orexigen Therapeutics announces data from CORDiabetes trial for Contrave

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

FDA schedules Advisory Committee meeting to review Orexigen's Contrave NDA

FDA schedules Advisory Committee meeting to review Orexigen's Contrave NDA

Fructose makes cells mature into fat cells in belly fat, study finds

Fructose makes cells mature into fat cells in belly fat, study finds

Data on Qnexa to be featured in six presentations at ADA annual meeting

Data on Qnexa to be featured in six presentations at ADA annual meeting

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

FDA assigns PDUFA action date for Orexigen's Contrave NDA review

FDA assigns PDUFA action date for Orexigen's Contrave NDA review

Selection of candidate in oncology programme triggers EUR 2.5 million milestone payment to Evotec

Selection of candidate in oncology programme triggers EUR 2.5 million milestone payment to Evotec

Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC

Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

FDA accepts Orexigen's Contrave NDA for treatment of obesity

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials

Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials

Atherotech to showcase VAP Cholesterol Test at NLA Scientific Sessions 2010

Atherotech to showcase VAP Cholesterol Test at NLA Scientific Sessions 2010

GENFIT announces milestone as compound developed in partnership enters the clinic

GENFIT announces milestone as compound developed in partnership enters the clinic

Atherotech to showcase VAP Cholesterol Test at Internal Medicine 2010

Atherotech to showcase VAP Cholesterol Test at Internal Medicine 2010

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Studies show association between high levels of vitamin D and decreased risk of heart disease

Studies show association between high levels of vitamin D and decreased risk of heart disease

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.